Results 101 to 110 of about 19,507 (228)

Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis

Lupus Science and Medicine
Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods Adverse event (AE) reports in the FAERS ...
Huqun Li, Wenlong Xie, Chongshu Wang, Cuilian Guo   +3 more
doaj   +1 more source

Characteristics of “Hard-to-Use” Press-Through-Package Sheets: An Analysis of Information Collected by Marketing Specialists of a Japanese Medical Wholesaler

Patient Preference and Adherence, 2020
Kenji Kabeya,1 Hiroki Satoh,2,3 Satoko Hori,4 Yasumasa Miura,5 Yasufumi Sawada2 1Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan; 2Laboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The ...
Kabeya K, Satoh H, Hori S, Miura Y, Sawada Y   +4 more
doaj  

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorthiazide, among Palestinian hypertensive patients

Therapeutics and Clinical Risk Management, 2016
Abdel Naser Zaid,1 Masshour Ghanem,2 Dua’a Shweiki,1 Hala Shtewi,1 Raja’ Shaheen,1 Sondos Al Helaly,1 Zeina Khayyat,1 Rowa’a Al Ramahi,1 Sa’ed H Zyoud1 1Department of Pharmacy, Faculty of Medicine & Health Sciences, An-Najah ...
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH   +8 more
doaj  

DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION] [PDF]

, 2012
This paper is a proposal to improve the quality of information available to pregnant patients in selecting treatment options. By providing drug companies with extended grants of exclusivity, the FDA has the ability to empower pregnant women to take ...
Goldstein, Lori M.
core  

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

Drug, Healthcare and Patient Safety, 2015
Michele Jara, Thomas Aquilina, Peter Aupperle, Adrian L Rabinowicz Acorda Therapeutics, Inc., Ardsley, NY, USA Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US ...
Jara M, Aquilina T, Aupperle P, Rabinowicz AL   +3 more
doaj  

Serious bacterial infections in patients with rheumatoid arthritis under anti‐TNF‐α therapy [PDF]

, 2017
Objective. With rising numbers of anti‐tumour necrosis factor α (TNF‐α) treatments for rheumatoid arthritis (RA), Crohn's disease and other conditions, physicians unaware of potential pitfalls are increasingly likely to encounter associated severe ...
Hasler, P., Kroesen, S., Tyndall, A., Widmer, A. F.   +3 more
core  

Unemployment Insurance and Older Workers in the United States [PDF]

, 2008
People are living longer and healthier lives at the same time that layoffs are increasing and pension plans are being curtailed. As the era of longevity progresses, unemployment among older Americans is likely to be a growing problem.
Charlotte Muller, Oleg Volkov
core  

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

BMC Gastroenterology
Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological
Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao   +7 more
doaj   +1 more source

Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA [PDF]

, 2006
Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA\u27s pharmaceutical data and the resultant restrictions on open discourse.
Ankelhed, Daniel, Hansson, Anders, Helmersson, Anders   +2 more
core   +1 more source